COMPANY:

Fulgent Genetics

"Fulgent Genetics, Inc...announced it has been awarded a five-year contract by the U.S. Department of Veterans Affairs (VA) to provide hereditary cancer, pharmacogenetic and other genetic testing to Veterans."

"Fulgent Genetics, Inc...announced two upcoming poster presentations at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1 to 5, 2023."

"Mission Bio announced...that it has entered a strategic partnership with Fulgent Genetics to broaden the accessibility of single-cell multiomics for drug development and clinical research...The partnership will allow drug developers and researchers to leverage the Mission Bio Tapestri system along with Fulgent's other services for biomarker discovery, clinical research, and single-cell measurable residual disease diagnostic (scMRD) development at scale, Mission Bio said in a statement."

"Fulgent Genetics...announced today that it has completed an acquisition of Fulgent Pharma Holdings, Inc. ('Fulgent Pharma'), an independent clinical-stage, therapeutics development company focused on the development of innovative cancer treatments. Under the terms of the agreement, Fulgent Genetics acquired Fulgent Pharma for a total purchase price of approximately $100 million, subject to adjustments, to be paid with a combination of cash on hand and shares of common stock of Fulgent Genetics. The combined company plans to offer a vertically integrated solution to combat cancer with the potential to unlock significant long-term upside for both the therapeutic and diagnostic businesses, while effectively managing risk....Attractive Lead Therapeutic Candidate FID-007...is a proprietary nanoencapsulated formulation of paclitaxel developed to improve the overall solubility profile of paclitaxel."

"Helio Genomics ("Helio"), and its commercial partner, Fulgent Genetics (NASDAQ: FLGT) ("Fulgent") announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses code for HelioLiver™, enabling a reimbursement pathway for potential increased access and broader adoption of innovative surveillance tests for liver cancer in the U.S. The code will become effective on October 1, 2022."

"Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics...to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test."

"Helio Health...and its commercial partner, Fulgent Genetics, Inc...today announced the commercial launch of HelioLiver™, a multi-analyte blood test that incorporates cell free DNA (cfDNA) methylation patterns and serum protein markers for the detection of hepatocellular carcinoma (HCC) – the most common form of liver cancer. HelioLiver can detect HCC at its earliest stages when lesions are still very small, an area where traditional standard-of-care imaging tools often fall short, with the potential to enable more curative treatment options known to increase five-year survival rates by up to 13 times compared to when cancer has metastasized."

"Helio Health...and Fulgent Genetics, Inc...announced its upcoming late-breaking poster presentation on the performance of HelioLiver, a multi-analyte blood test that utilizes both cell-free DNA (cfDNA) methylation patterns and protein tumor markers for the detection of hepatocellular carcinoma (HCC), at The Liver Meeting® 2021. The annual meeting is hosted by the American Association for the Study of Liver Diseases (AASLD) and will be held virtually November 12-15, 2021."